Nuvation Bio Inc (Class A) Live Stock Price Today, Share Analysis and Chart

Name: Nuvation Bio Inc - Ordinary Shares - Class A: Is Infosys Ltd. worth buying?
Item: Nuvation Bio Inc - Ordinary Shares - Class A
Rating: 0.96916675
Author: Trendlyne DVM scores

Weak Stock

about

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-g...

4.72 -0.07 (-1.46%)

51.59% Fall from 52W High

4.2M

XNYS Volume

XNYS 22 May, 2026 5:30 PM (EDT)

Board Meeting

The next board meeting for Nuvation Bio Inc (Class A) is on 26 May 2026 for the purpose of TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA See details

Low Financial Strength

16.7 / 100

Expensive Valuation

11.0 / 100

Technically Bearish

33.2 / 100

Weak Stock These stocks have poor scores across the board. Investors should be very cautious with these stocks View Similar Embed DVM

1Yr Price target upside is 161%

9 analysts

Nuvation Bio Inc (Class A) Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Nuvation Bio Inc (Class A) Live Stock Price Today, Share Analysis and Chart

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-g...

51.59% Fall from 52W High

SWOT Analysis

Nuvation Bio Inc (Class A) Live Price Chart